 The FDA has issued a complete response letter regarding the marketing application for FibroGen Incs NASDAQ: FGEN roxadustat for anemia of chronic kidney disease CKD. The letter indicates the FDA will not approve the roxadustat NDA in its present form and has requested an additional clinical study of roxadustat be conducted. 